Novo Nordisk disclosed during its Q4 2025 earnings call that generic versions of semaglutide could reach the U.S. market as early as 2031, following the expiration of key compound patents. The Danish pharmaceutical company also confirmed it is in discussions with multiple generic manufacturers about authorized generic agreements that could bring lower-cost versions to market even sooner.

CEO Lars Fruergaard Jorgensen addressed the timeline directly during the February 28 investor call, acknowledging that pricing pressure from lawmakers, insurers, and patients has accelerated the company's planning around patent strategy.

"We recognize that access and affordability are the defining challenges for this drug class," Jorgensen said. "We are committed to ensuring semaglutide remains available to patients who need it, including through authorized generic pathways."

The Patent Landscape

Semaglutide's intellectual property protection rests on multiple patents, each covering different aspects of the drug. The core compound patent, covering the semaglutide molecule itself, expires in 2032 in the United States [1]. However, Novo Nordisk holds additional patents on formulation, delivery devices, and manufacturing processes that extend protection for specific products further.

For Wegovy (injectable semaglutide for weight management), the relevant device and formulation patents extend to approximately 2034. For Ozempic (injectable semaglutide for type 2 diabetes), similar protections run through 2033. Rybelsus, the oral formulation, has SNAC absorption technology patents that provide protection through 2035 [1].

Patent attorneys tracking the GLP-1 space note that these dates are not absolute. Generic manufacturers can file Paragraph IV certifications challenging patent validity, potentially bringing generics to market before patent expiration. Teva Pharmaceutical and Mylan (now part of Viatris) have both signaled interest in semaglutide generics, though neither has confirmed ANDA filings.

Authorized Generics: A Faster Path

The more immediate development is Novo Nordisk's exploration of authorized generic agreements. An authorized generic is manufactured by or for the brand-name company and sold at a lower price, typically 15-30% below the branded version. Unlike true generics, authorized generics don't require separate FDA approval because they use the identical formulation.

Dr. Jami Kinton, a health economics researcher at the University of Michigan, explained that authorized generics serve a dual purpose for brand manufacturers. "They capture revenue that would otherwise go to generic competitors, and they allow the company to control the narrative around quality and supply," she said.

Novo Nordisk has not named its authorized generic partners, but industry analysts at Bernstein Research identified Sandoz and Hikma Pharmaceuticals as likely candidates based on existing manufacturing relationships [2].

What This Means for Drug Prices

The current list prices for Novo Nordisk's semaglutide products are substantial. Wegovy carries a list price of approximately $1,349 per month, while Ozempic lists at around $935 per month [3]. After insurance negotiation, patients typically pay less, but out-of-pocket costs still exceed $300 per month for many commercially insured patients and far more for the uninsured.

Generic entry historically reduces drug prices by 80-90% within several years of first generic availability, according to the FDA's Office of Generic Drugs [4]. If that pattern holds, generic semaglutide injections could eventually cost $100-$200 per month at retail.

However, biosimilar and generic peptide drugs have a more complex history than small-molecule generics. The manufacturing requirements for peptide drugs are more demanding, which limits the number of generic manufacturers that can enter the market and keeps prices higher than small-molecule generic patterns suggest.

Antonio Ciaccia, president of 46brooklyn Research, a drug pricing transparency organization, cautioned against assuming steep price drops. "Peptide generics don't behave like your typical generic antibiotic or statin," he noted. "The manufacturing complexity and limited number of capable producers will likely keep generic GLP-1 prices higher than people hope."

The Compounding Pharmacy Factor

Novo Nordisk's generic timeline also intersects with the ongoing controversy over compounded semaglutide. The FDA has maintained that semaglutide is no longer on its drug shortage list as of February 2025, which should restrict compounding pharmacies from producing copies. But legal challenges and enforcement gaps have allowed some compounding to continue [5].

An authorized generic at a lower price point could undercut the compounding market by offering patients an FDA-approved alternative that is more affordable than the branded product. This appears to be part of Novo Nordisk's strategic calculus.

Impact on Current Patients

For people currently taking Wegovy, Ozempic, or Rybelsus, the practical impact is limited in the near term. The earliest authorized generics would likely appear in 2028 or 2029, and true generics not until 2031 or later.

Patients should continue working with their prescribers and insurance plans to manage current costs. Several programs exist for cost reduction: Novo Nordisk's patient assistance programs cover eligible uninsured patients, and the company's savings cards reduce copays for commercially insured patients to as low as $25 per month for qualifying prescriptions.

The timeline also puts pressure on competing GLP-1 manufacturers. Eli Lilly, which markets Mounjaro and Zepbound (tirzepatide), faces its own patent expirations starting in the mid-2030s. The prospect of affordable semaglutide could influence Lilly's pricing strategy well before generics actually arrive.

Sources

  1. U.S. Patent and Trademark Office, Orange Book Patent Listings for Semaglutide. 2026.
  2. Bernstein Research. "GLP-1 Patent Cliff Analysis." February 2026.
  3. GoodRx. "Semaglutide Price Comparison." March 2026.
  4. FDA Office of Generic Drugs. "Generic Drug Competition and Pricing." 2024.
  5. FDA. "Compounding and the FDA: Questions and Answers." Updated January 2026.